Study to Evaluate Safety and Dosimetry of Lutathera in Adolescent Patients With GEP-NETs and PPGLs

Recruitment & Eligibility

Status: Active, not recruiting

Sex: All

Target Recruitment: Not specified

Inclusion Criteria

Key Inclusion Criteria: 1. GEP-NET cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven, G1 or G2 (Ki-67 index =< 20%), well differentiated GEP-NET. or PPGL cohort: presence of metastasized or locally advanced, inoperable (curative intent), histologically proven PPGL. 2. Patients from 12 to < 18 years of age at the time of enrollment. 3. Expression of somatostatin receptors confirmed by a somatostatin receptor imaging (SRI) modality within 3 months prior to enrollment, with tumor uptake observed in the target lesions more or equal to the normal liver uptake. 4. Performance status as determined by Karnofsky score >= 50 or Lansky Play-Performance Scale score >= 50. 5. Parent's ability to understand and the willingness to sign a written informed consent document for adolescents as determined by local regulations. Adolescents will sign assent along with parental/legal guardian consent or will co-sign consent with parent/legal guardian in accordance with local regulation, prior to participation in the study. Key Exclusion Criteria: 1. Laboratory parameters: 1. Estimated creatinine clearance calculated by the Cockroft-Gault method < 70 mL/min 2. Hb concentration <5.0 mmol/L (<8.0 g/dL); WBC <2x109/L; platelets <75x109/L. 3. Total bilirubin >3 x ULN for age. 4. Serum albumin <3.0 g/dL unless prothrombin time is within the normal range. 2. Established or suspected pregnancy. 3. Breastfeeding female patients unless they accept to discontinue breastfeeding from the 1st dose until 3 months after the last administration of study drug. 4. Female patients of child-bearing potential, unless they are using highly effective methods of contraception during treatment and for 6 months after the last dose of Lutathera. 5. Sexually active male patients, unless they agree to remain abstinent or be willing to use effective methods of contraception. 6. Patients for whom in the opinion of the investigator other therapeutic options are considered more appropriate than the therapy offered in the study, based on patient and disease characteristics. 7. Current spontaneous urinary incontinence. 8. Other known co-existing malignancies except non-melanoma skin cancer and carcinoma in situ of the uterine cervix, unless definitively treated and proven no evidence of recurrence for 5 years. 9. Hypersensitivity to the study drug active substance or to any of the excipients. 10. Patients with any other significant medical, psychiatric, or surgical condition, currently uncontrolled by treatment, which may interfere with the completion of the study. 11. Patient with known incompatibility to CT Scans with I.V. contrast due to allergic reaction or renal insufficiency. If such a patient can be imaged with MRI, then the patient would not be excluded. 12. Patients who received any investigational agent within the last 30 days.

Exclusion Criteria

Not provided

Study & Design

Study Type: Interventional

Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Absorbed radiation doses in target organ;Incidence of adverse events (AEs) and lab toxicities after 1st Lutathera administration

Secondary Outcome Measures

Name	Time	Method
Incidence of adverse events (AEs) during the short-term follow-up;Incidence of adverse events (AEs) during the long term follow-up;Calculated organ absorbed doses based on imaging radioactivity concentration data;Pharmacokinetics (PK) parameters based on blood radioactivity concentration data

Related Trials

Cephalexin Extended Release and Clavulanate Potassium Tablets in Patients with Upper Respiratory Tract Infection and Uncomplicated Skin & Soft Tissue Infection.

Phase 4

Sun Pharma Laboratories Ltd

Updated 8/21/2023

Phase 2 study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs, pheochromocytoma and paragangliomas

Phase 1

Advanced Accelerator Applications SA

Updated 8/26/2024

A multicenter open-label study to evaluate safety and dosimetry of Lutathera in adolescent patients with somatostatin receptor positive gastroenteropancreatic neuroendocrine (GEP-NET) tumors, pheochromocytoma and paragangliomas

WithdrawnPhase 2

Advanced Accelerator Applications

Updated 4/9/2024

Phase 2 study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs, pheochromocytoma and paragangliomas

Phase 1

Advanced Accelerator Applications SA

Updated 9/2/2024

Phase 2 study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs, pheochromocytoma and paragangliomas

Phase 1

Advanced Accelerator Applications SA

Updated 12/6/2021

Phase 2 study to evaluate safety and dosimetry of Lutathera in adolescent patients with GEP-NETs, pheochromocytoma and paragangliomas

Phase 1

Advanced Accelerator Applications SA

Updated 3/2/2022